LifeMD, Inc. (NASDAQ:LFMD) Given Average Rating of “Buy” by Brokerages

Shares of LifeMD, Inc. (NASDAQ:LFMD) have received an average recommendation of “Buy” from the six ratings firms that are presently covering the stock, Marketbeat.com reports. Six research analysts have rated the stock with a buy rating. The average 1-year price objective among brokers that have covered the stock in the last year is $12.50.

A number of brokerages have recently weighed in on LFMD. B. Riley reiterated a “buy” rating and issued a $12.00 price objective on shares of LifeMD in a research report on Tuesday, May 21st. HC Wainwright reiterated a “buy” rating and issued a $12.00 price objective on shares of LifeMD in a research report on Friday, May 10th. KeyCorp began coverage on shares of LifeMD in a research note on Wednesday, June 5th. They issued an “overweight” rating and a $12.00 price target on the stock. Cantor Fitzgerald increased their price objective on LifeMD from $13.00 to $15.00 and gave the company an “overweight” rating in a research report on Thursday, May 9th. Finally, BTIG Research lifted their price objective on LifeMD from $13.00 to $14.00 and gave the stock a “buy” rating in a report on Tuesday, April 23rd.

LifeMD Stock Up 2.1 %

LFMD stock opened at $6.86 on Friday. LifeMD has a 1-year low of $3.31 and a 1-year high of $12.88. The company has a current ratio of 0.99, a quick ratio of 0.94 and a debt-to-equity ratio of 10.83. The stock’s fifty day simple moving average is $8.87 and its two-hundred day simple moving average is $8.26. The stock has a market cap of $285.10 million, a P/E ratio of -9.27 and a beta of 1.16.

LifeMD (NASDAQ:LFMD) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.06). The company had revenue of $44.14 million during the quarter, compared to analyst estimates of $42.66 million. Analysts expect that LifeMD will post -0.25 EPS for the current year.

Hedge Funds Weigh In On LifeMD

Several institutional investors have recently bought and sold shares of LFMD. Vanguard Group Inc. increased its stake in LifeMD by 12.5% during the first quarter. Vanguard Group Inc. now owns 1,155,193 shares of the company’s stock worth $11,875,000 after acquiring an additional 128,701 shares during the last quarter. G2 Investment Partners Management LLC boosted its holdings in shares of LifeMD by 23.9% in the fourth quarter. G2 Investment Partners Management LLC now owns 688,050 shares of the company’s stock valued at $5,704,000 after purchasing an additional 132,850 shares during the period. Ancora Advisors LLC boosted its holdings in shares of LifeMD by 97.8% in the first quarter. Ancora Advisors LLC now owns 137,760 shares of the company’s stock valued at $1,416,000 after purchasing an additional 68,110 shares during the period. Acadian Asset Management LLC lifted its holdings in LifeMD by 261.8% during the first quarter. Acadian Asset Management LLC now owns 116,655 shares of the company’s stock worth $1,198,000 after buying an additional 84,413 shares during the period. Finally, Jump Financial LLC lifted its holdings in LifeMD by 50.2% during the fourth quarter. Jump Financial LLC now owns 111,738 shares of the company’s stock worth $926,000 after buying an additional 37,339 shares during the period. Institutional investors own 35.52% of the company’s stock.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.